| output.txt | +---1- Oral Abstract Session A Prostate Cancer | | Oral Abstract Session A Prostate Cancer.ts | | ~$ll Transcript.docx | | | +---PRESENTATION216877 | | abstract-TALAPRO2_Phase_3_study_of_talazoparib_TALA__enzalu..pdf | | slides-TALAPRO2_Phase_3_study_of_talazoparib_TALA__enzalu..pptx | | | +---PRESENTATION216883 | | abstract-Rucaparib_for_metastatic_castrationresistant_prost..pdf | | slides-Rucaparib_for_metastatic_castrationresistant_prost..pptx | | | +---PRESENTATION217305 | +---PRESENTATION217437 | | slides-Welcome_of_the_Day..pptx | | | +---PRESENTATION217438 | +---PRESENTATION217465 | | slides-Discussion..pptx | | | +---PRESENTATION217585 | | abstract-Patientlevel_data_metaanalysis_of_a_multimodal_art..pdf | | slides-Patientlevel_data_metaanalysis_of_a_multimodal_art..pptx | | | +---PRESENTATION217586 | | abstract-FORMULA509_A_multicenter_randomized_trial_of_posto..pdf | | slides-FORMULA509_A_multicenter_randomized_trial_of_posto..pptx | | | +---PRESENTATION217648 | | slides-Discussion..pptx | | | \---PRESENTATION217676 +---10- Keynote | | Keynote.ts | | | +---PRESENTATION215307 | | slides-Ending_Cancer_as_We_Know_It_Predicting_Future_Canc..pptx | | | +---PRESENTATION217290 | \---PRESENTATION217291 +---11- Innovations and Multidisciplinary Care in Early- and Late-Stage Urothelial Cancer | | Innovations and Multidisciplinary Care in Early- and Late-Stage Urothelial Cancer.ts | | | +---PRESENTATION215181 | | slides-NextGeneration_Therapies_in_NonmuscleInvasive_Blad..pptx | | | +---PRESENTATION215182 | | slides-Innovative_and_Pragmatic_Methods_to_Study_BCG_Unre..pptx | | | +---PRESENTATION215184 | | slides-Radiation_Therapy_in_Oligometastatic_and_Local_Rec..pptx | | | +---PRESENTATION215186 | +---PRESENTATION215329 | | slides-Sequencing_Systemic_Therapies_and_Looking_to_the_H..pptx | | | +---PRESENTATION215515 | +---PRESENTATION216876 | | slides-Optimizing_Survival_for_Patients_With_MuscleInvasi..pptx | | | +---PRESENTATION217343 | | abstract-A_phase_II_trial_of_riskenabled_therapy_after_init..pdf | | slides-A_phase_II_trial_of_riskenabled_therapy_after_init..pptx | | | \---PRESENTATION217463 +---12 AND 13- VIDEO + POSTER SESSION Trials in Progress B Urothelial Carcinoma | +-----VIDEO-- | | +---1 | | | posters-Randomized_phase_III_clinical_trial_of_neoadjuvant..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | slides-Randomized_phase_III_clinical_trial_of_neoadjuvant..pptx | | | | | +---2 | | | posters-A_phase_II_trial_of_intravesical_chemoimmunotherap..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | slides-A_phase_II_trial_of_intravesical_chemoimmunotherap..pptx | | | | | +---3 | | | posters-Phase_II_trial_of_lurbinectedin_combined_with_avel..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | +---4 | | | posters-First_in_human_FIH_phase_11b_study_evaluating_KIN3..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | slides-First_in_human_FIH_phase_11b_study_evaluating_KIN3..pptx | | | | | +---5 | | | posters-Phase_2_multicenter_openlabel_basket_trial_of_emna..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | \---6 | | posters-TROPHUU01_cohort_5_Evaluation_of_maintenance_sacit..pptx | | Program Guide – ASCO Meeting Program Guide.ts | | | +---PRESENTATION216852 | | posters-Randomized_phase_III_clinical_trial_of_neoadjuvant..pptx | | slides-Randomized_phase_III_clinical_trial_of_neoadjuvant..pptx | | | +---PRESENTATION216853 | | posters-A_phase_II_trial_of_intravesical_chemoimmunotherap..pptx | | slides-A_phase_II_trial_of_intravesical_chemoimmunotherap..pptx | | | +---PRESENTATION216854 | | posters-A_phase_II_study_of_riskbased_stratification_after..pptx | | | +---PRESENTATION216855 | | posters-A_phase_III_randomized_trial_of_eribulin_E_with_or..pptx | | | +---PRESENTATION216856 | | posters-Study_EV104_Phase_1_study_of_intravesical_enfortum..pptx | | | +---PRESENTATION216857 | | posters-Safety_and_efficacy_of_the_erdafitinib_erda_intrav..pptx | | | +---PRESENTATION216858 | | posters-SunRISe4_TAR200_plus_cetrelimab_or_cetrelimab_alon..pptx | | | +---PRESENTATION216859 | | posters-SPADE_Design_of_a_realworld_observational_study_of..pptx | | | +---PRESENTATION216860 | | posters-Phase_3_KEYNOTE905EV303_Perioperative_pembrolizuma..pptx | | | +---PRESENTATION216861 | +---PRESENTATION216862 | | posters-A_phase_2_basket_study_of_tucatinib_and_trastuzuma..pptx | | | +---PRESENTATION216863 | | posters-Perioperative_enfortumab_vedotin_EV_plus_pembroliz..pptx | | | +---PRESENTATION216864 | | posters-Alliance_A032002_ART_Phase_II_randomized_trial_of_..pptx | | | +---PRESENTATION216865 | | posters-Phase_II_trial_of_lurbinectedin_combined_with_avel..pptx | | | +---PRESENTATION216866 | | posters-Phase_2_KEYNOTE057_cohort_C_Pembrolizumab_pembro_w..pptx | | | +---PRESENTATION216867 | | posters-TROPHYU01_cohort_6_Sacituzumab_govitecan_SG_SG_plu..pptx | | | +---PRESENTATION216868 | | posters-First_in_human_FIH_phase_11b_study_evaluating_KIN3..pptx | | slides-First_in_human_FIH_phase_11b_study_evaluating_KIN3..pptx | | | +---PRESENTATION216869 | | posters-Phase_2_clinical_study_evaluating_the_efficacy_and..pptx | | | +---PRESENTATION216870 | +---PRESENTATION216871 | | posters-A_phase_1_openlabel_trial_to_evaluate_feasibility_..pptx | | | +---PRESENTATION216872 | | posters-Phase_2_multicenter_openlabel_basket_trial_of_emna..pptx | | | +---PRESENTATION216873 | | posters-TROPHUU01_cohort_5_Evaluation_of_maintenance_sacit..pptx | | | \---PRESENTATION216874 | posters-Atezolizumab_with_platinum_and_etoposide_chemother..pptx | +---14- Oral Abstract Session B Urothelial Carcinoma | | Oral Abstract Session B Urothelial Carcinoma.ts | | | +---PRESENTATION216466 | | abstract-Final_overall_survival_OS_analysis_of_atezolizumab..pdf | | slides-Final_overall_survival_OS_analysis_of_atezolizumab..pptx | | | +---PRESENTATION216467 | | abstract-Extended_followup_results_from_the_CheckMate_274_t..pdf | | slides-Extended_followup_results_from_the_CheckMate_274_t..pptx | | | +---PRESENTATION216468 | | abstract-Pembrolizumab_pembro_monotherapy_for_patients_pts_..pdf | | slides-Pembrolizumab_pembro_monotherapy_for_patients_pts_..pptx | | | +---PRESENTATION216471 | | slides-Discussion..pptx | | | +---PRESENTATION216851 | | slides-Discussion..pptx | | | +---PRESENTATION217446 | +---PRESENTATION217476 | +---PRESENTATION217499 | \---PRESENTATION217831 | abstract-Atezolizumab_atezo__platinumgemcitabine_pltgem_vs_..pdf | slides-Atezolizumab_atezo__platinumgemcitabine_pltgem_vs_..pptx | +---15- Supportive Care for Patients With Urothelial Carcinoma | | Supportive Care for Patients With Urothelial Carcinoma.ts | | | +---PRESENTATION215187 | +---PRESENTATION215188 | +---PRESENTATION215189 | +---PRESENTATION215190 | +---PRESENTATION215191 | | slides-Chair..pptx | | | +---PRESENTATION215192 | +---PRESENTATION215194 | +---PRESENTATION215330 | | slides-Panelist..pptx | | | \---PRESENTATION217344 | abstract-Patientreported_outcomes_PROs_in_cisplatinineligib..pdf | slides-Patientreported_outcomes_PROs_in_cisplatinineligib..pptx | +---16- Rapid Abstract Session Biomarkers of Response and Risk Stratification in Genitourinary Cancers | | Rapid Abstract Session Biomarkers of Response and Risk Stratification in Genitourinary.ts | | | +---PRESENTATION216525 | | abstract-Overall_survival_OS_and_efficacy_results_of_second..pdf | | slides-Overall_survival_OS_and_efficacy_results_of_second..pptx | | | +---PRESENTATION216526 | | abstract-Biomarker_analysis_from_the_phase_3_CheckMate_9ER_..pdf | | slides-Biomarker_analysis_from_the_phase_3_CheckMate_9ER_..pptx | | | +---PRESENTATION216535 | | abstract-Biomarkers_of_response_to_enfortumab_vedotin_EV_in..pdf | | slides-Biomarkers_of_response_to_enfortumab_vedotin_EV_in..pptx | | | +---PRESENTATION217306 | +---PRESENTATION217447 | +---PRESENTATION217610 | | abstract-Nivolumab_plus_ipilimumab_for_the_treatment_of_pos..pdf | | slides-Nivolumab_plus_ipilimumab_for_the_treatment_of_pos..pptx | | | +---PRESENTATION217611 | | abstract-European_Association_of_Urology_EAU_Testicular_Can..pdf | | slides-European_Association_of_Urology_EAU_Testicular_Can..pptx | | | \---PRESENTATION217644 | slides-Welcome_of_the_Day..pptx | +---17 AND 18- VIDEO + POSTER SESSION Trials in Progress C Renal Cell Cancer_ Adrenal, Penile, Urethral, and Testicular Cancers | +-----VIDEO-- | | +---1 | | | abstract-NOVAII_Part_2_study_to_evaluate_the_safety_and_eff..pdf | | | posters-NOVAII_Part_2_study_to_evaluate_the_safety_and_eff..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | +---2 | | | abstract-P3BEP_ANZUP_1302_An_international_randomized_phase..pdf | | | posters-P3BEP_ANZUP_1302_An_international_randomized_phase..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | slides-P3BEP_ANZUP_1302_An_international_randomized_phase..pptx | | | | | \---3 | | abstract-A_multicenter_prospective_validation_study_of_the_..pdf | | posters-A_multicenter_prospective_validation_study_of_the_..pptx | | Program Guide – ASCO Meeting Program Guide.ts | | | +---PRESENTATION216695 | +---PRESENTATION216696 | +---PRESENTATION216697 | +---PRESENTATION216698 | +---PRESENTATION216700 | +---PRESENTATION216701 | +---PRESENTATION216702 | +---PRESENTATION216703 | +---PRESENTATION216706 | +---PRESENTATION216707 | +---PRESENTATION216709 | +---PRESENTATION216712 | +---PRESENTATION216713 | +---PRESENTATION216714 | +---PRESENTATION216715 | +---PRESENTATION216717 | +---PRESENTATION216718 | +---PRESENTATION217623 | +---PRESENTATION217671 | +---PRESENTATION217702 | +---PRESENTATION217752 | +---PRESENTATION217841 | \---PRESENTATION217895 +---19- Rapid Abstract Session Renal Cell Cancer and Rare Tumors | | Rapid Abstract Session Renal Cell Cancer and Rare Tumors.ts | | | +---PRESENTATION216520 | | abstract-Treatmentfree_survival_TFS_outcomes_from_the_phase..pdf | | slides-Treatmentfree_survival_TFS_outcomes_from_the_phase..pptx | | | +---PRESENTATION216532 | | abstract-Outcomes_by_IMDC_risk_in_the_COSMIC313_phase_3_tri..pdf | | slides-Outcomes_by_IMDC_risk_in_the_COSMIC313_phase_3_tri..pptx | | | +---PRESENTATION216534 | | abstract-CaboPoint_Interim_results_from_a_phase_2_study_of_..pdf | | slides-CaboPoint_Interim_results_from_a_phase_2_study_of_..pptx | | | +---PRESENTATION216690 | | abstract-Safety_and_efficacy_of_immune_checkpoint_inhibitor..pdf | | slides-Safety_and_efficacy_of_immune_checkpoint_inhibitor..pptx | | | +---PRESENTATION216691 | | abstract-Interim_analysis_of_the_prospective_COTRIMS_Cologn..pdf | | slides-Interim_analysis_of_the_prospective_COTRIMS_Cologn..pptx | | | +---PRESENTATION217274 | | slides-Chair..pptx | | | \---PRESENTATION217448 | posters-Moderated_Panel_Discussion..pptx | slides-Moderated_Panel_Discussion..pptx | +---2- Advanced Prostate Cancer New Targets, New Drugs, New Victories | | Advanced Prostate Cancer New Targets, New Drugs, New Victories.ts | | | +---PRESENTATION215148 | | slides-New_Targets_New_Concepts_for_Metastatic_Castration..pptx | | | +---PRESENTATION215149 | +---PRESENTATION215151 | | slides-The_Androgen_Receptor_Remains_the_Main_Driver_of_D..pptx | | | +---PRESENTATION215152 | | slides-Treatment_Combinations_for_Patients_Starting_Andro..pptx | | | +---PRESENTATION215153 | | slides-How_to_Best_Use_Current_Drugs_Treatment_Sequencing..pptx | | | +---PRESENTATION215154 | +---PRESENTATION215493 | +---PRESENTATION217337 | | abstract-Efficacy_and_safety_of_darolutamide_DARO_in_combin..pdf | | slides-Efficacy_and_safety_of_darolutamide_DARO_in_combin..pptx | | | \---PRESENTATION217650 | abstract-Final_overall_survival_OS_in_PROpel_abiraterone_ab..pdf | slides-Final_overall_survival_OS_in_PROpel_abiraterone_ab..pptx | +---20- Managing Renal Cell Carcinoma at All Stages From Research to Practice | | Managing Renal Cell Carcinoma at All Stages From Research to Practice.ts | | | +---PRESENTATION215196 | | slides-The_EverChanging_Pathologic_Classification_of_Rena..pptx | | | +---PRESENTATION215198 | | slides-Adjuvant_Therapies_in_Renal_Cell_Carcinoma_Are_New..pptx | | | +---PRESENTATION215199 | | slides-_Clinical_Trial_Updates_in_Radiation_Oncology__..pptx | | | +---PRESENTATION215200 | | slides-Management_of_Nonclear_Cell_Renal_Cell_Carcinoma..pptx | | | +---PRESENTATION215201 | | slides-Systemic_Treatment_for_Recurrent_Metastatic_Diseas..pptx | | | +---PRESENTATION215202 | +---PRESENTATION215513 | +---PRESENTATION216389 | | slides-Improving_Functional_Outcomes_in_Localized_Renal_C..pptx | | | +---PRESENTATION217345 | | abstract-Outcomes_of_patients_with_brain_metastases_from_re..pdf | | slides-Outcomes_of_patients_with_brain_metastases_from_re..pptx | | | \---PRESENTATION217464 +---21- Moving the Needle Forward Multidisciplinary Care of Penile and Testicular Cancer | | Moving the Needle Forward Multidisciplinary Care of Penile and Testicular Cancer.ts | | | +---PRESENTATION215212 | +---PRESENTATION215213 | | slides-HPV_and_Penile_Cancer..pptx | | | +---PRESENTATION215214 | +---PRESENTATION215215 | | slides-How_Do_You_Best_Treat_Early_Metastatic_Seminoma_Ra..pptx | | | +---PRESENTATION215216 | | slides-How_Do_You_Best_Treat_Early_Metastatic_Seminoma_Ch..pptx | | | +---PRESENTATION215217 | | slides-How_Do_You_Best_Treat_Early_Metastatic_SeminomaSur..pptx | | | +---PRESENTATION215218 | +---PRESENTATION215219 | | slides-Dissecting_the_Dissection_in_Penile_Cancer..pptx | | | \---PRESENTATION217771 | abstract-Penile_squamous_cell_carcinoma_PSCC_with_elevated_..pdf | slides-Penile_squamous_cell_carcinoma_PSCC_with_elevated_..pptx | +---22- Oral Abstract Session C Renal and Rare Tumors | | Oral Abstract Session C Renal and Rare Tumors.ts | | | +---PRESENTATION216519 | | abstract-Nivolumab_plus_cabozantinib_vs_sunitinib_for_first..pdf | | slides-Nivolumab_plus_cabozantinib_vs_sunitinib_for_first..pptx | | | +---PRESENTATION216521 | | abstract-Results_from_phase_3_study_of_sup89supZrDFOgirentu..pdf | | slides-Results_from_phase_3_study_of_sup89supZrDFOgirentu..pptx | | | +---PRESENTATION216692 | | abstract-Longitudinal_evaluation_of_plasma_miR371_to_detect..pdf | | slides-Longitudinal_evaluation_of_plasma_miR371_to_detect..pptx | | | +---PRESENTATION217275 | | slides-Discussion..pptx | | | +---PRESENTATION217277 | +---PRESENTATION217449 | +---PRESENTATION217554 | | slides-Discussion..pptx | | | +---PRESENTATION217555 | \---PRESENTATION217707 | abstract-Comparative_costeffectiveness_of_alternative_imagi..pdf | slides-Comparative_costeffectiveness_of_alternative_imagi..pptx | +---23- Multidisciplinary Perspectives on Challenging Renal Cell Carcinoma Cases | | Multidisciplinary Perspectives on Challenging Renal Cell Carcinoma Cases.ts | | | +---PRESENTATION215204 | +---PRESENTATION215206 | | slides-Balancing_Biology_and_Risk_Active_Surveillance_for..pptx | | | +---PRESENTATION215207 | | slides-Management_of_Delayed_Oligometastatic_Disease_Radi..pptx | | | +---PRESENTATION215209 | | slides-Consolidation_Therapy_After_Immunotherapy_Surgery..pptx | | | +---PRESENTATION215210 | | slides-Consolidation_Therapy_After_Immunotherapy_Medical_..pptx | | | +---PRESENTATION215211 | +---PRESENTATION215510 | | slides-Chair..pptx | | | +---PRESENTATION215511 | | slides-Management_of_Delayed_Oligometastatic_Disease_Surg..pptx | | | \---PRESENTATION217346 | abstract-spanEffect_of_treatment_of_residual_disease_after_..pdf | slides-spanEffect_of_treatment_of_residual_disease_after_..pptx | +---3 and 4- VIDEO + POSTER Session Trials in Progress A Prostate Cancer | +-----VIDEO-- | | +---1 | | | abstract-TALAPRO3_A_phase_3_doubleblind_randomized_study_of..pdf | | | posters-TALAPRO3_A_phase_3_doubleblind_randomized_study_of..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | +---2 | | | abstract-CAPItello280_A_phase_III_study_of_capivasertib_and..pdf | | | posters-CAPItello280_A_phase_III_study_of_capivasertib_and..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | +---3 | | | abstract-A_phase_2_study_of_immunogenic_cell_death_inducer_..pdf | | | posters-A_phase_2_study_of_immunogenic_cell_death_inducer_..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | +---4 | | | abstract-Darolutamide_plus_androgendeprivation_therapy_ADT_..pdf | | | posters-Darolutamide_plus_androgendeprivation_therapy_ADT_..pptx | | | Program Guide – ASCO Meeting Program Guide.ts | | | | | \---5 | | abstract-A_multicenter_prospective_observational_study_of_p..pdf | | posters-A_multicenter_prospective_observational_study_of_p..pptx | | Program Guide – ASCO Meeting Program Guide.ts | | | +---PRESENTATION217233 | | abstract-Extreme_bipolar_androgen_therapy_with_darolutamide..pdf | | posters-Extreme_bipolar_androgen_therapy_with_darolutamide..pptx | | | +---PRESENTATION217234 | | abstract-Alliance_A031902_CASPAR_A_randomized_phase_ph_3_tr..pdf | | posters-Alliance_A031902_CASPAR_A_randomized_phase_ph_3_tr..pptx | | | +---PRESENTATION217235 | | abstract-A_multicenter_prospective_observational_study_of_p..pdf | | posters-A_multicenter_prospective_observational_study_of_p..pptx | | | +---PRESENTATION217237 | | abstract-Randomized_trial_of_five_or_two_MRIguided_adaptive..pdf | | posters-Randomized_trial_of_five_or_two_MRIguided_adaptive..pptx | | | +---PRESENTATION217238 | | abstract-Randomized_trial_of_MRIguided_salvage_radiotherapy..pdf | | posters-Randomized_trial_of_MRIguided_salvage_radiotherapy..pptx | | | +---PRESENTATION217239 | | abstract-Phase_12a_study_of_AZD5305_a_novel_polyadenosine_d..pdf | | posters-Phase_12a_study_of_AZD5305_a_novel_polyadenosine_d..pptx | | | +---PRESENTATION217241 | | abstract-TALAPRO3_A_phase_3_doubleblind_randomized_study_of..pdf | | posters-TALAPRO3_A_phase_3_doubleblind_randomized_study_of..pptx | | | +---PRESENTATION217242 | | abstract-Evolution_Phase_II_study_of_radionuclide_sup177sup..pdf | | posters-Evolution_Phase_II_study_of_radionuclide_sup177sup..pptx | | | +---PRESENTATION217243 | | abstract-Neoadjuvant_PARP_inhibition_prior_to_prostatectomy..pdf | | posters-Neoadjuvant_PARP_inhibition_prior_to_prostatectomy..pptx | | | +---PRESENTATION217245 | | abstract-Darolutamide_plus_androgendeprivation_therapy_ADT_..pdf | | posters-Darolutamide_plus_androgendeprivation_therapy_ADT_..pptx | | | +---PRESENTATION217246 | | abstract-VIOLET_A_phase_III_trial_evaluation_of_radioligand..pdf | | posters-VIOLET_A_phase_III_trial_evaluation_of_radioligand..pptx | | | +---PRESENTATION217247 | | abstract-Phase_III_study_of_local_or_systemic_therapy_inten..pdf | | posters-Phase_III_study_of_local_or_systemic_therapy_inten..pptx | | | +---PRESENTATION217248 | | abstract-Survival_outcomes_of_metastatic_castrationresistan..pdf | | posters-Survival_outcomes_of_metastatic_castrationresistan..pptx | | | +---PRESENTATION217250 | | abstract-NRGGU011_A_phase_II_doubleblinded_placebocontrolle..pdf | | posters-NRGGU011_A_phase_II_doubleblinded_placebocontrolle..pptx | | | +---PRESENTATION217251 | | abstract-A_phase_II_trial_modifying_metabolic_syndrome_and_..pdf | | posters-A_phase_II_trial_modifying_metabolic_syndrome_and_..pptx | | | +---PRESENTATION217252 | | abstract-A_phase_12_study_of_REGN4336_a_PSMAxCD3_bispecific..pdf | | posters-A_phase_12_study_of_REGN4336_a_PSMAxCD3_bispecific..pptx | | | +---PRESENTATION217253 | | abstract-Radiation_therapy_and_irreversible_electroporation..pdf | | posters-Radiation_therapy_and_irreversible_electroporation..pptx | | | +---PRESENTATION217254 | | abstract-Angelica_herbal_supplement_AGNCognIQ_acute_dose_sa..pdf | | posters-Angelica_herbal_supplement_AGNCognIQ_acute_dose_sa..pptx | | | +---PRESENTATION217255 | | abstract-A_realworld_registry_of_patients_with_metastatic_c..pdf | | posters-A_realworld_registry_of_patients_with_metastatic_c..pptx | | slides-A_realworld_registry_of_patients_with_metastatic_c..pptx | | | +---PRESENTATION217256 | | abstract-CAPItello280_A_phase_III_study_of_capivasertib_and..pdf | | posters-CAPItello280_A_phase_III_study_of_capivasertib_and..pptx | | | +---PRESENTATION217257 | | abstract-A_phase_III_doseescalation_study_of_fractionated_2..pdf | | posters-A_phase_III_doseescalation_study_of_fractionated_2..pptx | | | +---PRESENTATION217258 | | abstract-CYCLONE_3_A_phase_3_randomized_doubleblind_placebo..pdf | | posters-CYCLONE_3_A_phase_3_randomized_doubleblind_placebo..pptx | | | +---PRESENTATION217259 | | abstract-A_phase_2_expansion_study_of_ARV766_a_PROTACsup_su..pdf | | posters-A_phase_2_expansion_study_of_ARV766_a_PROTACsup_su..pptx | | | +---PRESENTATION217260 | | abstract-A_phase_II_singlearm_trial_of_niraparib_in_platinu..pdf | | posters-A_phase_II_singlearm_trial_of_niraparib_in_platinu..pptx | | | +---PRESENTATION217262 | | abstract-The_CONFIDENTP_trial_Clinical_implementation_of_ar..pdf | | posters-The_CONFIDENTP_trial_Clinical_implementation_of_ar..pptx | | | +---PRESENTATION217263 | | abstract-ENCORE_A_phase_2_trial_of_enfortumab_vedotin_EV_in..pdf | | posters-ENCORE_A_phase_2_trial_of_enfortumab_vedotin_EV_in..pptx | | | +---PRESENTATION217264 | | abstract-A_phase_IbII_study_IMMCO1_of_atezolizumab_plus_tiv..pdf | | posters-A_phase_IbII_study_IMMCO1_of_atezolizumab_plus_tiv..pptx | | | +---PRESENTATION217265 | | abstract-PRIMARY2_A_phase_III_multicentre_randomised_contro..pdf | | posters-PRIMARY2_A_phase_III_multicentre_randomised_contro..pptx | | | +---PRESENTATION217266 | | abstract-PROMISE_Registry_A_prostate_cancer_registry_of_out..pdf | | posters-PROMISE_Registry_A_prostate_cancer_registry_of_out..pptx | | | +---PRESENTATION217267 | | abstract-A_phase_2_study_of_immunogenic_cell_death_inducer_..pdf | | posters-A_phase_2_study_of_immunogenic_cell_death_inducer_..pptx | | | +---PRESENTATION217268 | | abstract-A_randomized_phase_II_trial_of_neoadjuvant_chemoki..pdf | | posters-A_randomized_phase_II_trial_of_neoadjuvant_chemoki..pptx | | | +---PRESENTATION217269 | | abstract-Phase_2_randomized_total_eradication_of_metastatic..pdf | | posters-Phase_2_randomized_total_eradication_of_metastatic..pptx | | | +---PRESENTATION217270 | | abstract-AtezoCab_A_phase_II_study_of_cabozantinib_C_in_com..pdf | | posters-AtezoCab_A_phase_II_study_of_cabozantinib_C_in_com..pptx | | | +---PRESENTATION217621 | | abstract-LuCAB_A_phase_III_trial_evaluating_cabazitaxel_in_..pdf | | posters-LuCAB_A_phase_III_trial_evaluating_cabazitaxel_in_..pptx | | | +---PRESENTATION217622 | | abstract-AlphaBet_A_phase_III_trial_evaluating_the_combinat..pdf | | posters-AlphaBet_A_phase_III_trial_evaluating_the_combinat..pptx | | | +---PRESENTATION217792 | | abstract-A_multicenter_openlabel_randomized_dose_expansion_..pdf | | posters-A_multicenter_openlabel_randomized_dose_expansion_..pptx | | | \---PRESENTATION217851 | abstract-spanDASLHiCaP_A_randomized_phase_3_doubleblind_tri..pdf | posters-spanDASLHiCaP_A_randomized_phase_3_doubleblind_tri..pptx | +---5- Clinical Decision-Making in the Treatment of Localized Prostate Cancer Controversial Points | | Clinical Decision-Making in the Treatment of Localized Prostate Cancer C.ts | | | +---PRESENTATION215157 | | slides-Active_Surveillance_for_Favorable_IntermediateRisk..pptx | | | +---PRESENTATION215158 | | slides-Active_Surveillance_for_Favorable_IntermediateRisk..pptx | | | +---PRESENTATION215159 | | slides-Novel_Guidelines_for_PSMA_PET_Staging_of_Disease_W..pptx | | | +---PRESENTATION215160 | +---PRESENTATION215161 | | slides-Novel_Approaches_for_Risk_Stratification_of_Newly_..pptx | | | +---PRESENTATION215162 | +---PRESENTATION215163 | +---PRESENTATION215514 | | slides-Clinically_NodePositive_Prostate_Cancer_Surgery..pptx | | | +---PRESENTATION217340 | | abstract-PACEA_An_international_phase_3_randomised_controll..pdf | | slides-PACEA_An_international_phase_3_randomised_controll..pptx | | | +---PRESENTATION217584 | | abstract-10Year_efficacy_and_comorbidity_outcomes_of_a_phas..pdf | | slides-10Year_efficacy_and_comorbidity_outcomes_of_a_phas..pptx | | | \---PRESENTATION217717 | slides-Clinically_NodePositive_Prostate_Cancer_Radiation..pptx | +---6- Controversies in Androgen Deprivation and Testosterone Supplementation for Patients With Prostate Cancer | | Controversies in Androgen Deprivation and Testosterone Supp.ts | | | +---PRESENTATION215164 | | slides-Chair..pptx | | | +---PRESENTATION215165 | +---PRESENTATION215166 | +---PRESENTATION215167 | +---PRESENTATION215168 | +---PRESENTATION215169 | +---PRESENTATION215170 | | slides-Panelist..pptx | | | +---PRESENTATION215171 | \---PRESENTATION217341 | abstract-Testosterone_recovery_in_patients_with_prostate_ca..pdf | slides-Testosterone_recovery_in_patients_with_prostate_ca..pptx | +---7- Rapid Abstract Session Prostate Cancer | | Rapid Abstract Session Prostate Cancer.ts | | | +---PRESENTATION216884 | | abstract-Pembrolizumab_plus_docetaxel_for_patients_with_met..pdf | | slides-Pembrolizumab_plus_docetaxel_for_patients_with_met..pptx | | | +---PRESENTATION216888 | | abstract-Results_of_a_multicenter_randomized_phase_3_trial_..pdf | | slides-Results_of_a_multicenter_randomized_phase_3_trial_..pptx | | | +---PRESENTATION216889 | | abstract-Efficacy_and_safety_of_abiraterone_acetate_plus_pr..pdf | | slides-Efficacy_and_safety_of_abiraterone_acetate_plus_pr..pptx | | | +---PRESENTATION216890 | | abstract-Randomized_doubleblinded_phase_II_study_of_ketocon..pdf | | slides-Randomized_doubleblinded_phase_II_study_of_ketocon..pptx | | | +---PRESENTATION217443 | +---PRESENTATION217602 | | abstract-Niraparib_NIRA_with_abiraterone_acetate_and_predni..pdf | | slides-Niraparib_NIRA_with_abiraterone_acetate_and_predni..pptx | | | +---PRESENTATION217603 | | abstract-Firstinclass_oral_innate_immune_activator_BXCL701_..pdf | | slides-Firstinclass_oral_innate_immune_activator_BXCL701_..pptx | | | \---PRESENTATION217651 +---8- Rapid Abstract Session Urothelial Carcinoma | | Rapid Abstract Session Urothelial Carcinoma.ts | | | +---PRESENTATION216470 | | abstract-Cellfree_urinary_tumor_DNA_to_detect_minimal_resid..pdf | | slides-Cellfree_urinary_tumor_DNA_to_detect_minimal_resid..pptx | | | +---PRESENTATION216473 | | abstract-Randomised_phase_II_trial_of_adaptive_image_guided..pdf | | slides-Randomised_phase_II_trial_of_adaptive_image_guided..pptx | | | +---PRESENTATION216474 | | abstract-Benefit_of_wholepelvis_radiation_for_patients_with..pdf | | slides-Benefit_of_wholepelvis_radiation_for_patients_with..pptx | | | +---PRESENTATION216475 | | abstract-Coprimary_endpoint_analysis_of_HCRN_GU_16257_Phase..pdf | | slides-Coprimary_endpoint_analysis_of_HCRN_GU_16257_Phase..pptx | | | +---PRESENTATION216476 | | abstract-HCRN_GU14188_Phase_IbII_study_of_neoadjuvant_pembr..pdf | | slides-HCRN_GU14188_Phase_IbII_study_of_neoadjuvant_pembr..pptx | | | +---PRESENTATION216495 | +---PRESENTATION217336 | | abstract-Primary_analysis_of_TROPHYU01_cohort_2_a_phase_2_s..pdf | | slides-Primary_analysis_of_TROPHYU01_cohort_2_a_phase_2_s..pptx | | | +---PRESENTATION217445 | \---PRESENTATION217643 | slides-Welcome_of_the_Day..pptx | \---9- Addressing Challenges to Ensure Health Equity in Bladder Cancer | Addressing Challenges to Ensure Health Equity in Bladder Cancer.ts | +---PRESENTATION215172 +---PRESENTATION215173 +---PRESENTATION215177 | slides-Moderated_Panel_Discussion..pptx | +---PRESENTATION215328 | slides-The_Impact_of_the_Financial_Cost_How_Much_Is_It_Co..pptx | +---PRESENTATION215341 | slides-Its_Time_to_Talk_About_ValueBased_Care_and_Time_To..pptx | +---PRESENTATION215346 | slides-Addressing_Health_Equity_by_Expanding_Trial_Eligib..pptx | +---PRESENTATION215470 | slides-Eliminating_Differences_in_Outcomes_by_Race_and_Ge..pptx | +---PRESENTATION217342 | abstract-Gender_specific_differences_in_healthrelated_quali..pdf | slides-Gender_specific_differences_in_healthrelated_quali..pptx | \---PRESENTATION217834 slides-Introduction..pptx